New IVIG impurity‑detection claim

GC Biopharma said on April 6 that it has built a better way to look for a very specific problem in intravenous immunoglobulin, or IVIG: tiny clot-promoting contaminants that are hard to see inside a product that is, by design, almost entirely antibody. The company’s claim is not that IVIG is suddenly unsafe. It is that one of the trickiest safety questions in the field still starts with measurement, and measurement has been messy. This new assay is meant to make that mess smaller. That matters because IVIG sits in an awkward place in medicine. It is a workhorse therapy made from pooled human plasma. Doctors use it both to replace missing antibodies and to calm down misfiring immune systems. It is also a product class that has carried thrombosis warnings for years. The FDA lists many approved immune globulin products, and U.S. labels for IVIG products, including GC Biopharma’s ALYGLO, warn that thrombosis may occur with treatment. Older safety work also pushed all IVIG makers to take thromboembolic risk seriously after clotting events were linked to some products. (fda.gov) The contaminant at the center of this story is factor XI in its activated form, FXIa, or closely related procoagulant material. In plain English, it is the wrong plasma protein in the wrong product. Residual FXIa has been identified in the literature as a root cause of at least some IVIG-associated thromboembolic events, which is why manufacturers now talk so much about removing it during purification. GC Biopharma has already been promoting a manufacturing step called cation-exchange chromatography, or “G-XI” technology, to strip out FXIa from ALYGLO, and a 2023 paper from company-affiliated authors reported that this step drove FXIa to undetectable levels in their process. (frontiersin.org) But removal is only half the story. You also need a test that can tell whether anything is left. That is where GC Biopharma says the field has had a blind spot. In the company’s April 6 announcement, tied to a paper in the April 2026 issue of the Journal of Microbiology and Biotechnology, it says conventional assays can be thrown off by the sheer amount of IgG in IVIG and by heterophilic antibody interference. Those are the kinds of assay artifacts that can create false positives or hide trace impurities altogether. GC’s answer is an ELISA-based method with a selective “IgG Blocker” designed to let factor XI be measured without the background noise from the antibody product itself. (prnewswire.com) The important distinction is that this is an impurity-detection claim, not a new clinical outcome. GC Biopharma says the assay performed well enough to support precise factor XI measurement in IVIG, but the public evidence available today is still mostly the company’s own description of the paper and its significance. That does not make the claim false. It just means the practical impact will depend on whether regulators, manufacturers, and pharmacovigilance teams treat this as a better early-warning signal rather than just a nicer lab method. If they do, the change could be surprisingly concrete. Lot investigations after thrombotic events often run into a familiar problem: was the event driven by the patient’s baseline risk, the infusion conditions, or something in the product lot itself? A more reliable assay would not answer that whole question, but it could narrow it faster. It could help quality teams decide whether a lot-level signal is real. It could also make it harder for trace procoagulant contamination to hide behind assay interference, which is exactly the sort of technical detail that ends up mattering when a product is made from pooled plasma and infused straight into a vein.